Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...
Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...
Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...
Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...
Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Novo Nordisk (NVO) to DKK 900 from DKK 1,000 and keeps a Buy rating ...
Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...
DPA International on MSN4d
Novo Nordisk expands drug collaboration with Valo HealthDenmark's Novo Nordisk on Wednesday announced an expansion of its collaboration with Valo Health to discover and develop ...
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback